Autoimmune conditions affecting tear and saliva production have long frustrated both patients and physicians with limited treatment options beyond symptom management. The chronic inflammatory nature of Sjögren's disease, which can affect multiple organ systems, has resisted effective systemic interventions despite decades of research into various immunosuppressive approaches.
The RepurpSS-II trial demonstrated that combining leflunomide (20mg) with hydroxychloroquine (400mg) daily produced a statistically significant 3.7-point reduction in disease activity scores compared to placebo over 24 weeks. This combination therapy targeted the European Alliance disease activity index, with participants showing measurable improvements in systemic manifestations. The study enrolled adults aged 18-75 with baseline activity scores of at least 5 points, ensuring patients had meaningful disease burden warranting intervention.
This finding represents a notable advancement for a condition where treatment options have remained largely supportive rather than disease-modifying. Both medications are well-established with known safety profiles—leflunomide as an immunomodulator used in rheumatoid arthritis, and hydroxychloroquine as an antimalarial with anti-inflammatory properties. The combination approach leverages complementary mechanisms of action that appear synergistic in autoimmune contexts. However, the modest effect size and 24-week timeframe raise questions about long-term sustainability and clinical meaningfulness. The trial's replication design strengthens confidence, though broader validation across diverse populations remains necessary. For the estimated 4 million Americans with Sjögren's, this represents the first evidence-based systemic treatment option that moves beyond palliative care toward potentially disease-modifying intervention.